ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Merck KGaA invests in antibody-drug conjugates

by Michael McCoy
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

09835-buscon15-adc.jpg
Credit: Merck KGaA
Merck KGaA says its facility will be designed to handle materials with extremely low human exposure limits.

Merck KGaA plans to spend $65 million to expand a plant near Madison, Wisconsin, that makes cancer-fighting antibody-drug conjugates for drug industry customers. The German firm says it will add a building that will be one of the largest dedicated to producing highly potent active pharmaceutical ingredients (HPAPIs). The facility will also produce the linker compounds that join HPAPIs to antibodies for targeted delivery to cancer cells. Merck says the project should add about 50 full-time jobs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment